- Home
- SGLY vs APM Comparison
SGLY vs APM Comparison
Compare SGLY & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- APM
- Stock Information
- Founded
- SGLY 2001
- APM 2010
- Country
- SGLY United States
- APM United Kingdom
- Employees
- SGLY N/A
- APM N/A
- Industry
- SGLY
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- APM Health Care
- Exchange
- SGLY Nasdaq
- APM Nasdaq
- Market Cap
- SGLY 5.8M
- APM 4.1M
- IPO Year
- SGLY 2008
- APM 2018
- Fundamental
- Price
- SGLY $2.45
- APM $1.23
- Analyst Decision
- SGLY
- APM
- Analyst Count
- SGLY 0
- APM 0
- Target Price
- SGLY N/A
- APM N/A
- AVG Volume (30 Days)
- SGLY 41.6K
- APM 7.0M
- Earning Date
- SGLY 02-26-2025
- APM 12-20-2024
- Dividend Yield
- SGLY N/A
- APM N/A
- EPS Growth
- SGLY N/A
- APM N/A
- EPS
- SGLY N/A
- APM 0.00
- Revenue
- SGLY $2,742,157.00
- APM N/A
- Revenue This Year
- SGLY N/A
- APM $157,729.10
- Revenue Next Year
- SGLY N/A
- APM N/A
- P/E Ratio
- SGLY N/A
- APM $363.68
- Revenue Growth
- SGLY N/A
- APM N/A
- 52 Week Low
- SGLY $1.27
- APM $0.46
- 52 Week High
- SGLY $7.65
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- SGLY 71.01
- APM 48.99
- Support Level
- SGLY $1.98
- APM $1.21
- Resistance Level
- SGLY $2.44
- APM $1.47
- Average True Range (ATR)
- SGLY 0.21
- APM 0.74
- MACD
- SGLY 0.08
- APM -0.02
- Stochastic Oscillator
- SGLY 94.25
- APM 7.67
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.